Novo Nordisk A/S (NVO)
124.08
+1.33
(+1.08%)
USD |
NYSE |
Apr 19, 09:54
Novo Nordisk Max Drawdown (5Y): 23.65% for March 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
Date | Value |
---|---|
March 31, 2024 | 23.65% |
February 29, 2024 | 23.65% |
January 31, 2024 | 23.65% |
December 31, 2023 | 23.65% |
November 30, 2023 | 23.65% |
October 31, 2023 | 23.65% |
September 30, 2023 | 23.65% |
August 31, 2023 | 23.81% |
July 31, 2023 | 26.66% |
June 30, 2023 | 26.66% |
May 31, 2023 | 26.66% |
April 30, 2023 | 26.66% |
March 31, 2023 | 26.66% |
February 28, 2023 | 26.66% |
January 31, 2023 | 26.66% |
December 31, 2022 | 26.66% |
November 30, 2022 | 26.66% |
October 31, 2022 | 26.66% |
September 30, 2022 | 26.66% |
August 31, 2022 | 26.66% |
July 31, 2022 | 26.66% |
June 30, 2022 | 26.66% |
May 31, 2022 | 28.40% |
April 30, 2022 | 28.40% |
March 31, 2022 | 28.40% |
Date | Value |
---|---|
February 28, 2022 | 32.26% |
January 31, 2022 | 38.47% |
December 31, 2021 | 43.74% |
November 30, 2021 | 43.74% |
October 31, 2021 | 43.74% |
September 30, 2021 | 43.74% |
August 31, 2021 | 46.14% |
July 31, 2021 | 46.14% |
June 30, 2021 | 46.14% |
May 31, 2021 | 46.14% |
April 30, 2021 | 46.14% |
March 31, 2021 | 46.14% |
February 28, 2021 | 46.14% |
January 31, 2021 | 46.14% |
December 31, 2020 | 46.14% |
November 30, 2020 | 46.14% |
October 31, 2020 | 46.14% |
September 30, 2020 | 46.14% |
August 31, 2020 | 46.14% |
July 31, 2020 | 46.14% |
June 30, 2020 | 46.14% |
May 31, 2020 | 46.14% |
April 30, 2020 | 46.14% |
March 31, 2020 | 46.14% |
February 29, 2020 | 46.14% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
23.65%
Minimum
Sep 2023
46.14%
Maximum
Apr 2019
37.19%
Average
43.74%
Median
Sep 2021
Max Drawdown (5Y) Benchmarks
Amgen Inc | 24.86% |
AstraZeneca PLC | 24.93% |
Sanofi SA | 33.52% |
Viking Therapeutics Inc | 89.26% |
Evaxion Biotech AS | -- |